Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Lapatinib

1500 mg po daily for 26 weeks or longer

Trial Locations (3)

11042

North Shore University Hospital, Lake Success

80045

University of Colorado Cancer Center, Aurora

03756

Norris Cotton Cancer Center, Lebanon

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

University of Colorado, Denver

OTHER

collaborator

North Shore University Hospital

OTHER

lead

Gary Schwartz

OTHER